Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
Patient Related Outcome Measures · 2023-01 · Volume 14 · 1-13
DOI: 10.2147/prom.s369584 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Patient Related Outcome Measures, 2023-01. Verfasst von Alvaro Gomez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
- Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
ORCID-Profile: Alvaro Gomez, Ioannis Parodis
Zitieren
APA
Gomez, A., Enman, Y., & Parodis, I. (2023). Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence. Patient Related Outcome Measures, Volume 14, 1-13. https://doi.org/10.2147/prom.s369584
Vancouver
Gomez A, Enman Y, Parodis I. Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence. Patient Related Outcome Measures. 2023;Volume 14:1-13. doi:10.2147/prom.s369584
BibTeX
@article{Gomez2023,
author = {Gomez, Alvaro and Enman, Yvonne and Parodis, Ioannis},
title = {Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence},
journal = {Patient Related Outcome Measures},
year = {2023},
volume = {Volume 14},
pages = {1--13},
doi = {10.2147/prom.s369584}
}
EUVIMED